To test this hypothesis, erythrocytes from PNH patients (PNH1–PNH4) were treated with ABO-matched sera containing CPV-104, sd-FH, pegcetacoplan, or eculizumab. This evidence concerns the gene ABO and paroxysmal nocturnal hemoglobinuria.